Sepsis Induces Interleukin 6, Gp130/JAK2/STAT3, and Muscle Wasting

Overview

Journal J Cachexia Sarcopenia Muscle

Date 2021 Nov 25

PMID 34821076

Citations 53

Authors

Lukas Zanders

Melanie Kny

Alexander Hahn

Sibylle Schmidt

Sebastian Wundersitz

Mihail Todiras

Ines Lahmann

Arnab Bandyopadhyay

Tobias Wollersheim

Lars Kaderali

Friedrich C Luft

Carmen Birchmeier

Steffen Weber-Carstens

Jens Fielitz

Affiliations

Soon will be listed here.

Abstract

Background: Sepsis and inflammation can cause intensive care unit-acquired weakness (ICUAW). Increased interleukin-6 (IL-6) plasma levels are a risk factor for ICUAW. IL-6 signalling involves the glycoprotein 130 (gp130) receptor and the JAK/STAT-pathway, but its role in sepsis-induced muscle wasting is uncertain. In a clinical observational study, we found that the IL-6 target gene, SOCS3, was increased in skeletal muscle of ICUAW patients indicative for JAK/STAT-pathway activation. We tested the hypothesis that the IL-6/gp130-pathway mediates ICUAW muscle atrophy.

Methods: We sequenced RNA (RNAseq) from tibialis anterior (TA) muscle of cecal ligation and puncture-operated (CLP) and sham-operated wildtype (WT) mice. The effects of the IL-6/gp130/JAK2/STAT3-pathway were investigated by analysing the atrophy phenotype, gene expression, and protein contents of C2C12 myotubes. Mice lacking Il6st, encoding gp130, in myocytes (cKO) and WT controls, as well as mice treated with the JAK2 inhibitor AG490 or vehicle were exposed to CLP or sham surgery for 24 or 96 h.

Results: Analyses of differentially expressed genes in RNAseq (≥2-log2-fold change, P < 0.01) revealed an activation of IL-6-signalling and JAK/STAT-signalling pathways in muscle of septic mice, which occurred after 24 h and lasted at least for 96 h during sepsis. IL-6 treatment of C2C12 myotubes induced STAT3 phosphorylation (three-fold, P < 0.01) and Socs3 mRNA expression (3.1-fold, P < 0.01) and caused myotube atrophy. Knockdown of Il6st diminished IL-6-induced STAT3 phosphorylation (-30.0%; P < 0.01), Socs3 mRNA expression, and myotube atrophy. JAK2 (- 29.0%; P < 0.01) or STAT3 inhibition (-38.7%; P < 0.05) decreased IL-6-induced Socs3 mRNA expression. Treatment with either inhibitor attenuated myotube atrophy in response to IL-6. CLP-operated septic mice showed an increased STAT3 phosphorylation and Socs3 mRNA expression in TA muscle, which was reduced in septic Il6st-cKO mice by 67.8% (P < 0.05) and 85.6% (P < 0.001), respectively. CLP caused a loss of TA muscle weight, which was attenuated in Il6st-cKO mice (WT: -22.3%, P < 0.001, cKO: -13.5%, P < 0.001; WT vs. cKO P < 0.001). While loss of Il6st resulted in a reduction of MuRF1 protein contents, Atrogin-1 remained unchanged between septic WT and cKO mice. mRNA expression of Trim63/MuRF1 and Fbxo32/Atrogin-1 were unaltered between CLP-treated WT and cKO mice. AG490 treatment reduced STAT3 phosphorylation (-22.2%, P < 0.05) and attenuated TA muscle atrophy in septic mice (29.6% relative reduction of muscle weight loss, P < 0.05). The reduction in muscle atrophy was accompanied by a reduction in Fbxo32/Atrogin-1-mRNA (-81.3%, P < 0.05) and Trim63/MuRF1-mRNA expression (-77.6%, P < 0.05) and protein content.

Conclusions: IL-6 via the gp130/JAK2/STAT3-pathway mediates sepsis-induced muscle atrophy possibly contributing to ICUAW.

Citing Articles

Atrophic C2C12 Myotubes Activate Inflammatory Response of Macrophages In Vitro.

Wu C, Tong Y, Huang J, Wang S, Kobori H, Zhang Z Cells. 2025; 14(5).

PMID: 40072046 PMC: 11899532. DOI: 10.3390/cells14050317.

Advancing sepsis diagnosis and immunotherapy machine learning-driven identification of stable molecular biomarkers and therapeutic targets.

Xiong W, Zhan Y, Xiao R, Liu F Sci Rep. 2025; 15(1):8333.

PMID: 40065038 PMC: 11894075. DOI: 10.1038/s41598-025-93010-8.

Elevated levels of S100A8 and S100A9 exacerbate muscle mitochondrial fragmentation in sepsis-induced muscle atrophy.

Huang D, Li Y, Guo Y, Weng M, Ye H, Zhang Y Commun Biol. 2025; 8(1):338.

PMID: 40021770 PMC: 11871300. DOI: 10.1038/s42003-025-07654-3.

Sarcopenia in Chronic Kidney Disease: A Narrative Review from Pathophysiology to Therapeutic Approaches.

Tsai C, Wang P, Hsiung T, Fan Y, Wu J, Kan W Biomedicines. 2025; 13(2).

PMID: 40002765 PMC: 11852367. DOI: 10.3390/biomedicines13020352.

The impact of tocilizumab treatment on the severity of inflammation and survival rates in sepsis is significantly influence by the timing of administration.

Tavaci T, Halici Z, Cadirci E, Ozkaraca M, Kasali K Inflammopharmacology. 2025; .

PMID: 39955435 DOI: 10.1007/s10787-025-01649-6.

References

Haberecht-Muller S, Kruger E, Fielitz J . Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation. Biomolecules. 2021; 11(9). PMC: 8468834. DOI: 10.3390/biom11091327. View

Busch K, Kny M, Huang N, Klassert T, Stock M, Hahn A . Inhibition of the NLRP3/IL-1β axis protects against sepsis-induced cardiomyopathy. J Cachexia Sarcopenia Muscle. 2021; 12(6):1653-1668. PMC: 8718055. DOI: 10.1002/jcsm.12763. View

Pena G, Cai B, Deitch E, Ulloa L . JAK2 inhibition prevents innate immune responses and rescues animals from sepsis. J Mol Med (Berl). 2010; 88(8):851-9. PMC: 3083634. DOI: 10.1007/s00109-010-0628-z. View

Ali N, OBrien Jr J, Hoffmann S, Phillips G, Garland A, Finley J . Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med. 2008; 178(3):261-8. DOI: 10.1164/rccm.200712-1829OC. View

Tanaka T, Narazaki M, Kishimoto T . IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014; 6(10):a016295. PMC: 4176007. DOI: 10.1101/cshperspect.a016295. View

Puppa M, Gao S, Narsale A, Carson J . Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia. FASEB J. 2013; 28(2):998-1009. PMC: 3898653. DOI: 10.1096/fj.13-240580. View

Weber-Carstens S, Schneider J, Wollersheim T, Assmann A, Bierbrauer J, Marg A . Critical illness myopathy and GLUT4: significance of insulin and muscle contraction. Am J Respir Crit Care Med. 2012; 187(4):387-96. DOI: 10.1164/rccm.201209-1649OC. View

Sharshar T, Bastuji-Garin S, Stevens R, Durand M, Malissin I, Rodriguez P . Presence and severity of intensive care unit-acquired paresis at time of awakening are associated with increased intensive care unit and hospital mortality. Crit Care Med. 2009; 37(12):3047-53. DOI: 10.1097/CCM.0b013e3181b027e9. View

Babon J, Kershaw N, Murphy J, Varghese L, Laktyushin A, Young S . Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity. 2012; 36(2):239-50. PMC: 3299805. DOI: 10.1016/j.immuni.2011.12.015. View

10.

Bodine S, Latres E, Baumhueter S, Lai V, Nunez L, Clarke B . Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547):1704-8. DOI: 10.1126/science.1065874. View

11.

Betz U, Bloch W, van den Broek M, Yoshida K, Taga T, Kishimoto T . Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med. 1998; 188(10):1955-65. PMC: 2212415. DOI: 10.1084/jem.188.10.1955. View

12.

Turnbull I, Wlzorek J, Osborne D, Hotchkiss R, Coopersmith C, Buchman T . Effects of age on mortality and antibiotic efficacy in cecal ligation and puncture. Shock. 2003; 19(4):310-3. DOI: 10.1097/00024382-200304000-00003. View

13.

Tierney M, Aydogdu T, Sala D, Malecova B, Gatto S, Puri P . STAT3 signaling controls satellite cell expansion and skeletal muscle repair. Nat Med. 2014; 20(10):1182-6. PMC: 4332844. DOI: 10.1038/nm.3656. View

14.

Winkelman C . The role of inflammation in ICU-acquired weakness. Crit Care. 2010; 14(4):186. PMC: 2945106. DOI: 10.1186/cc9187. View

15.

Weber-Carstens S, Deja M, Koch S, Spranger J, Bubser F, Wernecke K . Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study. Crit Care. 2010; 14(3):R119. PMC: 2911767. DOI: 10.1186/cc9074. View

16.

Wen Z, Zhong Z, Darnell Jr J . Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995; 82(2):241-50. DOI: 10.1016/0092-8674(95)90311-9. View

17.

Hoene M, Runge H, Haring H, Schleicher E, Weigert C . Interleukin-6 promotes myogenic differentiation of mouse skeletal muscle cells: role of the STAT3 pathway. Am J Physiol Cell Physiol. 2012; 304(2):C128-36. DOI: 10.1152/ajpcell.00025.2012. View

18.

Hui L, Yao Y, Wang S, Yu Y, Dong N, Li H . Inhibition of Janus kinase 2 and signal transduction and activator of transcription 3 protect against cecal ligation and puncture-induced multiple organ damage and mortality. J Trauma. 2009; 66(3):859-65. DOI: 10.1097/TA.0b013e318164d05f. View

19.

Huang N, Kny M, Riediger F, Busch K, Schmidt S, Luft F . Deletion of Nlrp3 protects from inflammation-induced skeletal muscle atrophy. Intensive Care Med Exp. 2017; 5(1):3. PMC: 5241267. DOI: 10.1186/s40635-016-0115-0. View

20.

von Haehling S, Morley J, Coats A, Anker S . Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2019. J Cachexia Sarcopenia Muscle. 2019; 10(5):1143-1145. PMC: 6818444. DOI: 10.1002/jcsm.12501. View